SCHEMBL10344857

SCHEMBL10344857

CC1(O)C(O)OC(CO)C(O)C1O

nearest known ligand 0.42

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
LGALS1 P09382 2/20 0.36
LGALS3 P17931 2/20 0.36
LGALS9 O00182 1/20 0.36
LGALS8 O00214 1/20 0.36
OGA O60502 7/20 0.35
HEXB P07686 2/20 0.35
HEXA P06865 1/20 0.35
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
CA12 O43570 3/20 0.33
CA1 P00915 3/20 0.33
CA2 P00918 3/20 0.33
CA9 Q16790 3/20 0.33
ALDH1A1 P00352 2/20 0.33
TSHR P16473 2/20 0.33
LMNA P02545 1/20 0.33
TDP1 Q9NUW8 1/20 0.33
PYGB P11216 2/20 0.33
GAA P10253 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5394485 1.00 LGALS1 (0.36) LGALS1LGALS3LGALS9LGALS8OGA
SCHEMBL29110844 1.00 LGALS1 (0.36) LGALS1LGALS3LGALS9LGALS8OGA
SCHEMBL6726689 1.00 LGALS1 (0.36) LGALS1LGALS3LGALS9LGALS8OGA
SCHEMBL4361557 1.00 LGALS1 (0.36) LGALS1LGALS3LGALS9LGALS8OGA
SCHEMBL6726688 1.00 LGALS1 (0.36) LGALS1LGALS3LGALS9LGALS8OGA
SCHEMBL5899047 1.00 LGALS1 (0.36) LGALS1LGALS3LGALS9LGALS8OGA
SCHEMBL338344 0.87 ADORA2A (0.38) LGALS1LGALS3LGALS9LGALS8OGA
SCHEMBL338345 0.87 ADORA2A (0.38) LGALS1LGALS3LGALS9LGALS8OGA
SCHEMBL14293911 0.87 ADORA2A (0.38) LGALS1LGALS3LGALS9LGALS8OGA
SCHEMBL1826901 0.87 ADORA2A (0.38) LGALS1LGALS3LGALS9LGALS8OGA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230130134-A1 METHOD OF TREATING VIRAL INFECTIONS WITH HEXOSE TYPE MONOSACCHARIDES AND ANALOGS THEREOF BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2023-04-27 US disclosed
WO-2021188586-A1 METHOD OF TREATING VIRAL INFECTIONS WITH HEXOSE TYPE MONOSACCHARIDES AND ANALOGS THEREOF BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2021-09-23 WO disclosed
US-20120276108-A1 MONOSACCHARIDE-BASED COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE AND INFLAMMATORY DERMATOLOGICAL DISEASES INTERTECH BIO (US) 2012-11-01 US disclosed
US-20120276108-A1 MONOSACCHARIDE-BASED COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE AND INFLAMMATORY DERMATOLOGICAL DISEASES INTERTECH BIO (US) 2012-11-01 US disclosed
WO-2012097052-A2 MONOSACCHARIDE-BASED COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE AND INFLAMMATORY DERMATOLOGICAL DISEASES INTERTECH BIO, LLC (US) 2012-07-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230130134-A1 METHOD OF TREATING VIRAL INFECTIONS WITH HEXOSE TYPE MONOSACCHARIDES AND ANALOGS THEREOF G6PD, FBP1, ALDOA LGALS1 232/4885LGALS3 292/4885LGALS9 490/4885
US-20120276108-A1 MONOSACCHARIDE-BASED COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE AND INFLAMMATORY DERMATOLOGICAL DISEASES IGF1R, IRS1, IGFBP1 LGALS1 109/4885LGALS3 409/4885LGALS9 605/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.